Cargando…

Treating epistaxis – who cares for a bleeding nose? A secondary data analysis of primary and secondary care

BACKGROUND: The primary objective was to describe outpatient treatment of epistaxis among different physicians based on a large patient population over a period of 10 years. The secondary objective was to evaluate the value of the practice fee as an instrument of allocation in patients with epistaxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Althaus, Annina E., Lüske, Jonas, Arendt, Ulrike, Dörks, Michael, Freitag, Michael H., Hoffmann, Falk, Jobski, Kathrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051091/
https://www.ncbi.nlm.nih.gov/pubmed/33858351
http://dx.doi.org/10.1186/s12875-021-01411-1
_version_ 1783679695617785856
author Althaus, Annina E.
Lüske, Jonas
Arendt, Ulrike
Dörks, Michael
Freitag, Michael H.
Hoffmann, Falk
Jobski, Kathrin
author_facet Althaus, Annina E.
Lüske, Jonas
Arendt, Ulrike
Dörks, Michael
Freitag, Michael H.
Hoffmann, Falk
Jobski, Kathrin
author_sort Althaus, Annina E.
collection PubMed
description BACKGROUND: The primary objective was to describe outpatient treatment of epistaxis among different physicians based on a large patient population over a period of 10 years. The secondary objective was to evaluate the value of the practice fee as an instrument of allocation in patients with epistaxis. METHODS: Anonymized statutory health insurance data (AOK Lower Saxony) of patients with a diagnosis of epistaxis treated between 2007 and 2016 were examined. Demographic data, accompanying diagnoses, medication and involved medical groups (general practitioners (GP), pediatricians, ear, nose and throat (ENT) specialists or other) were analyzed. Furthermore, we assessed whether the use of specialist groups changed after abolition of the practice fee in 2013. RESULTS: Epistaxis was responsible for 302,782 cases (160,963 patients). The distribution of cases was slightly in favor of ENT specialists vs. GP (119,170 vs. 110,352). The cases seen by GP and ENT specialists were comparable with regard to age and sex distribution. Hypertension, atrial fibrillation/flutter and an antithrombotic therapy were slightly more common among cases consulting a GP. The GP recorded more co-diagnoses than the ENT. The use of outpatient care and the proportions of the involved physicians scarcely fluctuated during the study period. Overall, 23,118 patients (14.4%) were diagnosed by both, GP and ENT during a relatively short time period. The practice fee remuneration had no impact on the consultation of the physician groups. CONCLUSION: The outpatient treatment of epistaxis constitutes a considerable medical and economic burden in Germany. Strengthening the primary medical sector (GP-centered care) is necessary to reach the goal of initially directing patients to primary care, providing specialists more time for severe cases and reducing the impact on public health balance sheets.
format Online
Article
Text
id pubmed-8051091
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80510912021-04-19 Treating epistaxis – who cares for a bleeding nose? A secondary data analysis of primary and secondary care Althaus, Annina E. Lüske, Jonas Arendt, Ulrike Dörks, Michael Freitag, Michael H. Hoffmann, Falk Jobski, Kathrin BMC Fam Pract Research Article BACKGROUND: The primary objective was to describe outpatient treatment of epistaxis among different physicians based on a large patient population over a period of 10 years. The secondary objective was to evaluate the value of the practice fee as an instrument of allocation in patients with epistaxis. METHODS: Anonymized statutory health insurance data (AOK Lower Saxony) of patients with a diagnosis of epistaxis treated between 2007 and 2016 were examined. Demographic data, accompanying diagnoses, medication and involved medical groups (general practitioners (GP), pediatricians, ear, nose and throat (ENT) specialists or other) were analyzed. Furthermore, we assessed whether the use of specialist groups changed after abolition of the practice fee in 2013. RESULTS: Epistaxis was responsible for 302,782 cases (160,963 patients). The distribution of cases was slightly in favor of ENT specialists vs. GP (119,170 vs. 110,352). The cases seen by GP and ENT specialists were comparable with regard to age and sex distribution. Hypertension, atrial fibrillation/flutter and an antithrombotic therapy were slightly more common among cases consulting a GP. The GP recorded more co-diagnoses than the ENT. The use of outpatient care and the proportions of the involved physicians scarcely fluctuated during the study period. Overall, 23,118 patients (14.4%) were diagnosed by both, GP and ENT during a relatively short time period. The practice fee remuneration had no impact on the consultation of the physician groups. CONCLUSION: The outpatient treatment of epistaxis constitutes a considerable medical and economic burden in Germany. Strengthening the primary medical sector (GP-centered care) is necessary to reach the goal of initially directing patients to primary care, providing specialists more time for severe cases and reducing the impact on public health balance sheets. BioMed Central 2021-04-15 /pmc/articles/PMC8051091/ /pubmed/33858351 http://dx.doi.org/10.1186/s12875-021-01411-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Althaus, Annina E.
Lüske, Jonas
Arendt, Ulrike
Dörks, Michael
Freitag, Michael H.
Hoffmann, Falk
Jobski, Kathrin
Treating epistaxis – who cares for a bleeding nose? A secondary data analysis of primary and secondary care
title Treating epistaxis – who cares for a bleeding nose? A secondary data analysis of primary and secondary care
title_full Treating epistaxis – who cares for a bleeding nose? A secondary data analysis of primary and secondary care
title_fullStr Treating epistaxis – who cares for a bleeding nose? A secondary data analysis of primary and secondary care
title_full_unstemmed Treating epistaxis – who cares for a bleeding nose? A secondary data analysis of primary and secondary care
title_short Treating epistaxis – who cares for a bleeding nose? A secondary data analysis of primary and secondary care
title_sort treating epistaxis – who cares for a bleeding nose? a secondary data analysis of primary and secondary care
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051091/
https://www.ncbi.nlm.nih.gov/pubmed/33858351
http://dx.doi.org/10.1186/s12875-021-01411-1
work_keys_str_mv AT althausanninae treatingepistaxiswhocaresforableedingnoseasecondarydataanalysisofprimaryandsecondarycare
AT luskejonas treatingepistaxiswhocaresforableedingnoseasecondarydataanalysisofprimaryandsecondarycare
AT arendtulrike treatingepistaxiswhocaresforableedingnoseasecondarydataanalysisofprimaryandsecondarycare
AT dorksmichael treatingepistaxiswhocaresforableedingnoseasecondarydataanalysisofprimaryandsecondarycare
AT freitagmichaelh treatingepistaxiswhocaresforableedingnoseasecondarydataanalysisofprimaryandsecondarycare
AT hoffmannfalk treatingepistaxiswhocaresforableedingnoseasecondarydataanalysisofprimaryandsecondarycare
AT jobskikathrin treatingepistaxiswhocaresforableedingnoseasecondarydataanalysisofprimaryandsecondarycare